SCM
ANIK icon

Sterling Capital Management’s Anika Therapeutics ANIK Stock Holding History

Sterling Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41K Sell
233
-180
-44% -$2.67K ﹤0.01% 2805
2026
Q1 		$5.99K Sell
413
-305
-42% -$3.54K ﹤0.01% 2649
2025
Q4 		$6.9K Sell
718
-142
-17% -$1.36K ﹤0.01% 2774
2025
Q3 		$8.08K Buy
860
+563
+190% +$5.38K ﹤0.01% 2605
2025
Q2 		$3.14K Buy
297
+113
+61% +$1.43K ﹤0.01% 2761
2025
Q1 		$2.77K Sell
184
-181
-50% -$3.01K ﹤0.01% 2454
2024
Q4 		$6.01K Buy
365
+324
+790% +$6.39K ﹤0.01% 2376
2024
Q3 		$1.01K Buy
+41
New +$1.06K ﹤0.01% 2523
2015
Q1 		– Sell
-44,916
Closed -$1.83M – 870
2014
Q4 		$1.83M Sell
44,916
-316
-0.7% -$12.4K 0.02% 430
2014
Q3 		$1.66M Buy
45,232
+1,037
+2% +$44.8K 0.02% 444
2014
Q2 		$2.05M Buy
44,195
+1,063
+2% +$47.3K 0.02% 341
2014
Q1 		$1.77M Buy
43,132
+31,362
+266% +$1.17M 0.02% 368
2013
Q4 		$449K Buy
11,770
+933
+9% +$28.8K ﹤0.01% 621
2013
Q3 		$259K Buy
+10,837
New +$243K ﹤0.01% 605

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Sterling Capital Management's ANIK Position: Q2 2026 in Review

Sterling Capital Management reduced its Anika Therapeutics (ANIK) stake by 44% in Q2 2026, selling an estimated $2.67K and leaving 233 shares worth $3.41K. The position accounts for ﹤0.01% of the portfolio, ranked #2805.

Sterling Capital Management first reported a position in ANIK in Q3 2013 and has held it in 14 quarters since. The position peaked at $2.05M in Q2 2014. 134 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Sterling Capital Management held 233 shares of Anika Therapeutics worth $3.41K as of Q2 2026.
  • Sterling Capital Management sold 180 Anika Therapeutics shares in Q2 2026, an estimated $2.67K.
  • Anika Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2805 holding.
  • Sterling Capital Management first reported a position in Anika Therapeutics in Q3 2013 and has held it in 14 quarters since.
  • Sterling Capital Management's Anika Therapeutics position peaked at $2.05M in Q2 2014.
  • 134 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.